EP3684424A4 - CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING - Google Patents

CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING Download PDF

Info

Publication number
EP3684424A4
EP3684424A4 EP18859613.4A EP18859613A EP3684424A4 EP 3684424 A4 EP3684424 A4 EP 3684424A4 EP 18859613 A EP18859613 A EP 18859613A EP 3684424 A4 EP3684424 A4 EP 3684424A4
Authority
EP
European Patent Office
Prior art keywords
chimeric antigen
antigen receptors
nfkb signaling
enhanced
enhanced nfkb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859613.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3684424A1 (en
Inventor
Marco L. DAVILLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of EP3684424A1 publication Critical patent/EP3684424A1/en
Publication of EP3684424A4 publication Critical patent/EP3684424A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP18859613.4A 2017-09-22 2018-09-11 CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING Pending EP3684424A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762561815P 2017-09-22 2017-09-22
US201762597128P 2017-12-11 2017-12-11
US201862640153P 2018-03-08 2018-03-08
US201862666385P 2018-05-03 2018-05-03
US201862666381P 2018-05-03 2018-05-03
PCT/US2018/050417 WO2019060174A1 (en) 2017-09-22 2018-09-11 CHIMERIC ANTIGENIC RECEPTORS WITH ENHANCED NFKB SIGNALING

Publications (2)

Publication Number Publication Date
EP3684424A1 EP3684424A1 (en) 2020-07-29
EP3684424A4 true EP3684424A4 (en) 2021-09-29

Family

ID=65810869

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859613.4A Pending EP3684424A4 (en) 2017-09-22 2018-09-11 CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING

Country Status (5)

Country Link
EP (1) EP3684424A4 (ja)
JP (1) JP2021500859A (ja)
AU (1) AU2018335266A1 (ja)
CA (1) CA3070861A1 (ja)
WO (1) WO2019060174A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2021514631A (ja) * 2018-02-26 2021-06-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための組成物および方法
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
SG10201908256RA (en) * 2019-09-06 2021-04-29 Nat Univ Singapore T cell modified with a synthetic receptor containing a single ITAM signaling motif
JP7439279B2 (ja) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド キメラ抗原受容体の最適化
CN115361968A (zh) * 2020-03-31 2022-11-18 弗莱德哈钦森癌症中心 在抗原靶向免疫疗法中增加抗原阴性细胞死亡
CN111411085A (zh) * 2020-04-10 2020-07-14 格源致善(上海)生物科技有限公司 一种嵌合抗原受体t细胞及其应用
WO2021244654A1 (en) * 2020-06-05 2021-12-09 Nanjing Legend Biotech Co., Ltd. Activation induced cytokine production in immune cells
US20240115608A1 (en) * 2021-02-10 2024-04-11 The Regents Of The University Of California Immune receptors with synthetic co-stimulatory domains
CN113203781B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的基于RGO-CS-Hemin@Pt NPs纳米材料和适配体检测GPC3的方法
WO2023245042A2 (en) * 2022-06-14 2023-12-21 H. Lee Moffitt Cancer Center And Research Institute Inc. Nkg2d expressing car-t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
US20140328812A1 (en) * 2003-11-05 2014-11-06 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542488B2 (en) * 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CN112410363A (zh) * 2014-08-19 2021-02-26 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140328812A1 (en) * 2003-11-05 2014-11-06 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2014127261A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADRIENNE H LONG ET AL: "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", NATURE MEDICINE, vol. 21, no. 6, 4 May 2015 (2015-05-04), New York, pages 581 - 590, XP055278553, ISSN: 1078-8956, DOI: 10.1038/nm.3838 *
DATABASE Geneseq [online] 9 August 2018 (2018-08-09), "Human 4-1BB intracellular domain, SEQ:21.", XP093123513, retrieved from EBI accession no. GSP:BFJ88468 Database accession no. BFJ88468 *
DIOGO GOMES-SILVA ET AL: "Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent", CELL REPORTS, vol. 21, no. 1, 1 October 2017 (2017-10-01), US, pages 17 - 26, XP055690717, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2017.09.015 *
LI GONGBO ET AL: "4-1BB enhancement of CAR T function requires NF-[kappa]B and TRAFs", JCI INSIGHT, vol. 3, no. 18, 20 September 2018 (2018-09-20), XP093035954, ISSN: 2379-3708, DOI: 10.1172/jci.insight.121322 *
LI GONGBO ET AL: "Mutation of the 41BB co-stimulatory domain enhances CAR signaling and mouse CD19-targeted CAR T cell function", 1 February 2017 (2017-02-01), XP009527374, Retrieved from the Internet <URL:https://www.researchgate.net/publication/314151105_Mutation_of_the_41BB_co-stimulatory_domain_enhances_CAR_signaling_and_mouse_CD19-targeted_CAR_T_cell_function> [retrieved on 20210506], DOI: 10.13140/RG.2.2.14247.75682 *
LI GONGBO ET AL: "Optimization of Murine 4-1BB Signaling Results in Enhanced CD19-Targeted CAR T Cell Function in Immune Competent Mice", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 23, no. 3, 1 March 2017 (2017-03-01), XP029931874, ISSN: 1083-8791, DOI: 10.1016/J.BBMT.2016.12.417 *
M. SADELAIN ET AL: "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), pages 388 - 398, XP055133523, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548 *
M. SADELAIN ET AL: "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, vol. 3, no. 4, 1 April 2013 (2013-04-01), US, pages 388 - 398, XP055287277, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0548 *
POSEY AVERY D ET AL: "Mixed Signals: Alteration of CD28 Signaling Motifs Improves Anti-Tumor Efficacy and Persistence of CAR T Cells", MOLECULAR THERAPY, vol. 5, no. S1, 1 May 2017 (2017-05-01), pages 154 - 154, XP055794713 *
See also references of WO2019060174A1 *

Also Published As

Publication number Publication date
AU2018335266A1 (en) 2020-02-06
EP3684424A1 (en) 2020-07-29
WO2019060174A1 (en) 2019-03-28
CA3070861A1 (en) 2019-03-28
JP2021500859A (ja) 2021-01-14

Similar Documents

Publication Publication Date Title
EP3684424A4 (en) CHIMERA ANTIGEN RECEPTORS WITH IMPROVED NFKB SIGNALING
EP3732191A4 (en) IMPROVED ANTIGENIC CHEMICAL RECEPTORS AND THEIR USES
IL277078A (en) Anti-CD33 chimeric antigen receptors and their uses
IL257138A (en) Chimeric antigen receptors with integrated controlled activities
EP3528851A4 (en) HETERODIMERIZABLE CHIMERIC ANTIGENIC RECEPTORS BASED ON CEREBLON
EP3580212A4 (en) REGULATION OF CHIMERIC ANTIGEN RECEPTORS
EP3658163A4 (en) NOVEL CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
EP3256496A4 (en) Chimeric antigen receptors
IL250536A0 (en) Chimeric antigen receptors
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
IL251030A0 (en) Chimeric antigen receptors
EP3274366B8 (en) Chimeric antigen receptor
IL270896A (en) CAR targets FLT3
EP3119425A4 (en) Regulatable chimeric antigen receptor
EP3134434A4 (en) Kappa/lambda chimeric antigen receptors
GB201617290D0 (en) Novel chimeric antigen receptors
EP3102236A4 (en) Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
EP3344295A4 (en) CHIMERIC ANTI-SIALYL TN ANTIGEN RECEPTORS
EP3347474A4 (en) CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP3518944A4 (en) ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
ZA202005837B (en) Cd83-binding chimeric antigen receptors
ZA201906321B (en) Chimeric antigen receptor
IL266950A (en) Chimeric chlorotoxin receptors
EP3585403A4 (en) CHEMERICAL ANTIGENIC RECEPTORS BINDING TO TIM3

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20210520BHEP

Ipc: C07K 16/28 20060101ALI20210520BHEP

Ipc: C07K 14/705 20060101ALI20210520BHEP

Ipc: C07K 14/725 20060101ALI20210520BHEP

Ipc: A61P 35/00 20060101ALI20210520BHEP

Ipc: C07H 21/04 20060101ALI20210520BHEP

Ipc: C07K 16/00 20060101ALI20210520BHEP

Ipc: C12N 5/16 20060101ALI20210520BHEP

Ipc: C12N 15/00 20060101ALI20210520BHEP

Ipc: A61K 39/00 20060101ALI20210520BHEP

Ipc: C12N 5/071 20100101ALI20210520BHEP

Ipc: A61K 48/00 20060101AFI20210520BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210827

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0783 20100101ALI20210823BHEP

Ipc: C07K 16/28 20060101ALI20210823BHEP

Ipc: C07K 14/705 20060101ALI20210823BHEP

Ipc: C07K 14/725 20060101ALI20210823BHEP

Ipc: A61P 35/00 20060101ALI20210823BHEP

Ipc: C07H 21/04 20060101ALI20210823BHEP

Ipc: C07K 16/00 20060101ALI20210823BHEP

Ipc: C12N 5/16 20060101ALI20210823BHEP

Ipc: C12N 15/00 20060101ALI20210823BHEP

Ipc: A61K 39/00 20060101ALI20210823BHEP

Ipc: C12N 5/071 20100101ALI20210823BHEP

Ipc: A61K 48/00 20060101AFI20210823BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240131